JP2024506016A5 - - Google Patents

Info

Publication number
JP2024506016A5
JP2024506016A5 JP2023547398A JP2023547398A JP2024506016A5 JP 2024506016 A5 JP2024506016 A5 JP 2024506016A5 JP 2023547398 A JP2023547398 A JP 2023547398A JP 2023547398 A JP2023547398 A JP 2023547398A JP 2024506016 A5 JP2024506016 A5 JP 2024506016A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506016A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015496 external-priority patent/WO2022170193A2/en
Publication of JP2024506016A publication Critical patent/JP2024506016A/ja
Publication of JP2024506016A5 publication Critical patent/JP2024506016A5/ja
Pending legal-status Critical Current

Links

JP2023547398A 2021-02-08 2022-02-07 免疫療法のためのt細胞免疫グロブリン及びムチンドメイン3(tim3)組成物及び方法 Pending JP2024506016A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147221P 2021-02-08 2021-02-08
US63/147,221 2021-02-08
PCT/US2022/015496 WO2022170193A2 (en) 2021-02-08 2022-02-07 T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy

Publications (2)

Publication Number Publication Date
JP2024506016A JP2024506016A (ja) 2024-02-08
JP2024506016A5 true JP2024506016A5 (https=) 2025-02-21

Family

ID=80819858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547398A Pending JP2024506016A (ja) 2021-02-08 2022-02-07 免疫療法のためのt細胞免疫グロブリン及びムチンドメイン3(tim3)組成物及び方法

Country Status (5)

Country Link
US (1) US20230374456A1 (https=)
EP (1) EP4288089A2 (https=)
JP (1) JP2024506016A (https=)
CN (1) CN117042794A (https=)
WO (1) WO2022170193A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202106058WA (en) * 2016-12-08 2021-07-29 Intellia Therapeutics Inc Modified guide rnas
JP2024534114A (ja) * 2021-08-24 2024-09-18 インテリア セラピューティクス,インコーポレイテッド 細胞療法用のプログラム細胞死タンパク質1(pd1)組成物及び方法
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026006390A2 (en) * 2024-06-26 2026-01-02 Intellia Therapeutics, Inc. Modified guide rnas for genome editing

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
JP3131222B2 (ja) 1991-12-24 2001-01-31 アイシス・ファーマシューティカルス・インコーポレーテッド ギャップを有する2′修飾オリゴヌクレオチド
JPH10500310A (ja) 1994-05-19 1998-01-13 ダコ アクティーゼルスカブ 淋菌及びトラコーマ クラミジアの検出のためのpna プローブ
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US20150376586A1 (en) 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
KR20230156800A (ko) 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
CN107921148A (zh) * 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
CA2985650A1 (en) * 2015-05-13 2016-11-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Enhancing endonuclease based gene editing in primary cells
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
LT3436077T (lt) * 2016-03-30 2025-06-25 Intellia Therapeutics, Inc. Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
SG10202106058WA (en) 2016-12-08 2021-07-29 Intellia Therapeutics Inc Modified guide rnas
CN109790518A (zh) * 2017-05-08 2019-05-21 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
EP4029943A1 (en) 2017-05-08 2022-07-20 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
US11738047B2 (en) * 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
WO2019147805A2 (en) 2018-01-26 2019-08-01 The Board Of Trustees Of The Leland Stanford Junior University Regulatory t cells targeted with chimeric antigen receptors
US11447769B2 (en) 2018-03-27 2022-09-20 The Trustees Of The University Of Pennsylvania Modified immune cells having enhanced function and methods for screening for same
AU2019282824C1 (en) 2018-06-08 2026-04-23 Intellia Therapeutics, Inc. Modified guide RNAS for gene editing
EP3581200A1 (en) 2018-06-13 2019-12-18 GEMoaB Monoclonals GmbH Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CN113227374A (zh) 2018-10-16 2021-08-06 因特利亚治疗公司 用于免疫疗法的组合物和方法
WO2020092057A1 (en) 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
CA3181340A1 (en) 2020-04-28 2021-11-04 Intellia Therapeutics, Inc. Methods of in vitro cell delivery

Similar Documents

Publication Publication Date Title
JP2025511899A5 (https=)
JP2023171775A5 (https=)
JP2022184985A5 (https=)
JP2023103258A5 (https=)
JP2023166402A5 (https=)
JP2021184963A5 (https=)
JP2024116190A5 (https=)
JP2023116721A5 (https=)
JP2023145572A5 (https=)
JP2025160243A5 (https=)
JP2025176106A5 (https=)
JP2022541332A5 (https=)
JP2023181322A5 (https=)
JP2023514727A5 (https=)
JP2023552816A5 (https=)
JP2022116141A5 (https=)
JP2024045126A5 (https=)
JP2025098156A5 (https=)
JP2023512729A5 (https=)
JP2023093656A5 (https=)
JP2023078173A5 (https=)
JP2024099716A5 (https=)
JP2025090801A5 (https=)
JP2025094038A5 (https=)
JP2024149687A5 (https=)